Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease
暂无分享,去创建一个
A. Colombo | A. Margonato | P. Della Bella | A. Cappelletti | P. Mazzone | C. Godino | L. Arrigoni | A. Salerno | F. Melillo | Michela Cera | F. Rubino | Paolo Mattiello | the INSIghT investigators | M. Cera